We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Questions Expanded Indication for Forest Labs’ Bystolic
FDA Questions Expanded Indication for Forest Labs’ Bystolic
January 8, 2010
FDA briefing documents for an advisory committee review of Forest Laboratories’ hypertension drug Bystolic say the primary endpoint of the study
to support the product was only marginally significant.